TCON Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 20:07):

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States...

Stats
Tagesvolumen	227 080
Durchschnittsvolumen	237 899
Marktkapitalisierung	84.36M
EPS	$0 ( 2024-03-05 )
Nächstes Ertragsdatum	( $-0.0600 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.85
ATR14	$0.0290 (1.56%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-12	Brown Scott B.	Buy	224 800	Employee Stock Option (Right to Buy)
2023-04-20	Brown Scott B.	Buy	3 500	Common Stock
2024-03-12	Theuer Charles	Buy	518 300	Employee Stock Option (Right to Buy)
2023-10-20	Theuer Charles	Buy	3 500	Common Stock
2023-04-20	Theuer Charles	Buy	3 500	Common Stock

INSIDER POWER
80.87
Last 100 transactions
Buy: 3 843 498 \| Sell: 406 947

Volumen Korrelation

Lang: 0.00 (neutral)

Kurz: -0.46 (neutral)

Signal:(36.002) Neutral

TRACON Pharmaceuticals Korrelation

10 Am meisten positiv korreliert
BBCP	0.855
DUOT	0.816

10 Am meisten negativ korreliert
BNIXU	-0.898

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

TRACON Pharmaceuticals Korrelation - Währung/Rohstoff

0.46
( neutral )

0.74
( moderate )

0.00
( neutral )

0.83
( strong )

0.72
( moderate )

-0.58
( weak negative )

TRACON Pharmaceuticals Finanzdaten

Annual	2023
Umsatz:	$12.05M
Bruttogewinn:	$12.03M (99.88 %)
EPS:	$-0.110

FY	2023
Umsatz:	$12.05M
Bruttogewinn:	$12.03M (99.88 %)
EPS:	$-0.110

FY	2022
Umsatz:	$0
Bruttogewinn:	$-16 000.00 (0.00 %)
EPS:	$-1.400

FY	2021
Umsatz:	$346 000
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1.660

Financial Reports:

No articles found.

TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.